PROPEL: A randomized, phase Ill trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).

Affiliation auteurs!!!! Error affiliation !!!!
TitrePROPEL: A randomized, phase Ill trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
Type de publicationJournal Article
Year of Publication2019
AuteursClarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Ye D, Mateo J, Goessl CDietrich, Kang J, Liu S, Saad F
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume37
Date PublishedMAR 1
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2019.37.7_suppl.TPS340